scholarly journals Design and development of a photoswitchable DFG-out kinase inhibitor

2021 ◽  
Vol 57 (78) ◽  
pp. 10043-10046
Author(s):  
Yongjin Xu ◽  
Chunxia Gao ◽  
Liliana Håversen ◽  
Thomas Lundbäck ◽  
Joakim Andréasson ◽  
...  

A photoswitchable DFG-out kinase inhibitor has been developed. The activity of the inhibitor can efficiently be regulated by light in both enzymatic and living cell assays.

2013 ◽  
Vol 176 ◽  
pp. 605-610 ◽  
Author(s):  
Paula Daza ◽  
Alberto Olmo ◽  
Daniel Cañete ◽  
Alberto Yúfera
Keyword(s):  

2014 ◽  
Vol 18 (4) ◽  
pp. 501-510 ◽  
Author(s):  
Neil J. Kallman ◽  
Chin Liu ◽  
Matthew H. Yates ◽  
Ryan J. Linder ◽  
J. Craig Ruble ◽  
...  

Blood ◽  
2011 ◽  
Vol 118 (13) ◽  
pp. 3657-3660 ◽  
Author(s):  
Jean-Claude Chomel ◽  
Marie-Laure Bonnet ◽  
Nathalie Sorel ◽  
Angelina Bertrand ◽  
Marie-Claude Meunier ◽  
...  

Abstract Sustained undetectable molecular residual disease (UMRD) is obtained in a minority of patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. It remains unclear whether these patients are definitively cured of their leukemia or whether leukemic stem cells (LSCs) persist in their BM. We have evaluated the presence of BCR-ABL–expressing marrow LSCs in 6 patients with chronic myeloid leukemia with sustained UMRD induced by IFN-α (n = 3), imatinib mesylate after IFN-α failure (n = 2), and dasatinib after imatinib intolerance (n = 1). Purified CD34+ cells were used for clonogenic and long-term culture-initiating cell assays performed on classic or HOXB4-expressing MS-5 feeders. Using this strategy, we identified BCR-ABL–expressing LSCs in all patients. Interestingly, long-term culture-initiating cell assays with MS-5/HOXB4 stromal feeders increased detected numbers of LSCs in 3 patients. The relation between LSC persistency and a potential risk of disease relapse for patients with durable UMRD (on or off tyrosine kinase inhibitor therapy) warrants further investigation.


2020 ◽  
Vol 20 (17) ◽  
pp. 1564-1575
Author(s):  
Prashant S. Kharkar

: Kinases remain one of the major attractive therapeutic targets for a large number of indications such as cancer, rheumatoid arthritis, cardiac failure and many others. Design and development of kinase inhibitors (ATP-competitive, allosteric or covalent) is a clinically validated and successful strategy in the pharmaceutical industry. The perks come with limitations, particularly the development of resistance to highly potent and selective inhibitors. When this happens, the cycle needs to be repeated, i.e., the design and development of kinase inhibitors active against the mutated forms. The complexity of tumor milieu makes it awfully difficult for these molecularly-targeted therapies to work. Every year newer and better versions of these agents are introduced in the clinic. Several computational approaches such as structure-, ligand-based or hybrid ones continue to live up to their potential in discovering novel kinase inhibitors. New schools of thought in this area continue to emerge, e.g., development of dual-target kinase inhibitors. But there are fundamental issues with this approach. It is indeed difficult to selectively optimize binding at two entirely different or related kinases. In addition to the conventional strategies, modern technologies (machine learning, deep learning, artificial intelligence, etc.) started yielding the results and building success stories. Computational tools invariably played a critical role in catalysing the phenomenal progress in kinase drug discovery field. The present review summarized the progress in utilizing computational methods and tools for discovering (mutant-)selective tyrosine kinase inhibitor drugs in the last three years (2017-2019). Representative investigations have been discussed, while others are merely listed. The author believes that the enthusiastic reader will be inspired to dig out the cited literature extensively to appreciate the progress made so far and the future prospects of the field.


Author(s):  
Conly L. Rieder

The behavior of many cellular components, and their dynamic interactions, can be characterized in the living cell with considerable spatial and temporal resolution by video-enhanced light microscopy (video-LM). Indeed, under the appropriate conditions video-LM can be used to determine the real-time behavior of organelles ≤ 25-nm in diameter (e.g., individual microtubules—see). However, when pushed to its limit the structures and components observed within the cell by video-LM cannot be resolved nor necessarily even identified, only detected. Positive identification and a quantitative analysis often requires the corresponding electron microcopy (EM).


2004 ◽  
Vol 171 (4S) ◽  
pp. 251-251
Author(s):  
Kazunori Hattori ◽  
Katsuyuki Iida ◽  
Akira Johraku ◽  
Sadamu Tsukamoto ◽  
Taeko Asano ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document